Operating from our new state-of-the-art manufacturing and distribution facility in Terbuny, Lipetsk Region, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to our own line of proprietary products that are approved by the Ministry of Health of Russian Federation.
For the last three years, the Russian Government has been highly focused on bolstering the development of Russia's domestic pharmaceutical industry. Our mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
The Russian pharmaceutical market is estimated to be valued at $60 billion by 2020, representing annual growth of at least 15%. The market is far from the ceiling of its astounding potential, and at Rafarma Pharmaceuticals, we are wholly dedicated to capitalizing on the emerging opportunities for growth.
As one of the foremost research companies in Russia, we possess a unique niche within the country's growing pharmaceutical market, leveraging our world-class production facility and exciting product portfolio to carve our path to become a major player in the international drug industry.
Backed by a diverse pharmaceutical product portfolio, Rafarma Pharmaceuticals provides shareholders and clients the opportunity to share in the expansion of what we believe will be a pharmaceuticals industry giant.
Number of employees: 461
U.S. Company Website: www.Rafarma.com
Russian Company Website: www.Rafarma.ru
Presentation: Rafarma Presentation
Fact Sheet: Rafarma Fact Sheet
Rafarma News: Rafarma NEWS
Facebook: Rafarma Facebook Page
Twitter: Rafarma Twitter Profile
Rafarma Plant Photo Gallery
- Russian Government is focused bolstering domestic pharmaceutical market, supporting local companies
Russian pharmaceutical sector expected to be valued at $10.7 billion by 2014, $60 billion by 2020
Company expects to produce proprietary and new hi-tech pharmaceutical developments from its world-class research facilities
Rafarma is the principle supplier to the Russian Public Health system and the Russian Army
Company growth is aimed far beyond the Russian market to a global pharmaceutical reach
Rafarma is currently applying to be quoted on the GXG market
Despite its early development stage, Rafarma has been conservatively valued at circa US$300 million
Rafarma is positioned to capitalize and grow from two significant variables saddling the Eastern European Pharmaceuticals market: growing demand and a struggling economy. The population of elderly citizens throughout Eastern Europe has grown alongside the region's economic turmoil.
These factors equate to increased favorability from both healthcare providers and individuals pursuing high-quality yet affordable pharmaceutical products. In addition, Russian government mandates requiring physicians to use Rafarma products create a solid and unique niche within the pharmaceutical industry.
If the progress continues as the government plans, the Russian pharmaceutical industry by 2020 could contribute 50% of drugs in circulation, 80% of which would be domestically developed.
Rafarma is on track to saturate the Russian market as a European-based specialist pharmaceutical producer. Its initiatives don't stop there - the company is also securing its foothold penetrate international markets such as Brazilian and the Southeast Asian sub-continent.
Manufacturing and Distribution Facility
Rafarma Pharmaceuticals has invested considerable funds in building a state-of-the-art production facility in the economic development zone in Terbuny, Lipetsk Region, approximately 300 km south of Moscow.
This multi-profile pharmaceutical plant has the capability and space to produce all types and forms of medical drugs of various pharmacological groups.
The project has been supported by the government of Lipetsk region of Russia, Ministry of Health of Russian Federation, and the Ministry of Industry and Trade of Russian Federation, which listed Rafarma Pharmaceuticals as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry.
Rafarma Pharmaceuticals' facility is being implemented in accordance with the government-developed Strategy of Development of Pharmaceutical Industry in Russia, which encourages the construction and improvement of modern production facilities in compliance with GMP standards to eliminate Russia's need to purchase certain pharmaceutical products outside of the country.
The Management Team
With highly experienced and ambitious leadership at the helm, Rafarma Pharmaceuticals has achieved rapid advancements in the pharmaceutical industry. The company's key management team is skilled with a diverse line of expertise that includes entrepreneurship, business management, international corporations, cash management, law, finance, corporate loans and more. Under the focused guidance of this core management team, Rafarma Pharmaceuticals is positioned to continue its progress and become a dominant figure in the Russian pharmaceutical market.
CEO and Director - Bruno Horn
Mr. Horn is the founder of his own consultancy based in Switzerland, specializing in steel trading and the pharmaceutical industry. Mr. Horn started his career as a trader in raw materials and semi-finished products, as well as, OEM products for Olivetti. Mr. Horn served as head of back office for Olivetti Group's financial operations. Mr. Horn was in charge of international flat steel trade structure for Olsher Metals, a US based group, before joining the Lucchini Group with their flat products sector and organizing the sales structure for the US. Mr. Horn, also served as independent consultant for CMM, a US based company active in the field of securitizations. Most recently, Mr. Horn was director of finance for MMK Steel of Russia. Mr. Horn brings significant experience in finance and operational management particularly in Russia markets.
CFO and Director - Sergey Brusnitsin, JD, PhD
Sergey Brusnitsin came to Rafarma from the position of Vice-Chief of the Federal Revenue Service of Russia, Interregional Inspection. Mr. Brusnitsin carries both a law degree from Moscow Financial and Industrial Academy and a PhD from Moscow State Univesity of Economics, Statistics and Information Systems. Mr. Brusnitsin's dissertation was on management of cash flows and loans in international corporations. Mr. Brusnitsin is a valuable asset for Rafarma with his tremendous expertise in international corporations, law and finance.
Secretary Treasurer - Alexander Ageev, JD
Alexander Ageev specializes in state-legal and financial law. Prior to joining Rafarma Pharmaceuticals, Mr. Ageev worked as a court session specialist secretary, assistant judge in the Arbitration court of Moscow, deputy chief of the organizational-control department of the Administration of Federal services, among others. He currently is the deputy general director of legal issues and information security for CJSC "Rafarma" in addition to his role as Secretary-Treasurer of Rafarma Pharmaceuticals.
|Market Value ||$4,076,681 ||a/o Apr 05, 2013 |
|Shares Outstanding ||83,894,399 ||a/o Oct 10, 2014 |
|Float ||11,287,187 ||a/o Oct 10, 2014 |
|Authorized Shares ||300,000,000 ||a/o Apr 01, 2013 |
Western States Transfer and Registrar, Inc.
1911 Ryan Park Avenue
Sandy, Utah 84092
Projected Revenue Estimates
2012 - $15,606,285
2013 - $142,488,845
2014 - $271,488,845
2015 - $317,000,000